|
pubmed:abstractText |
The discovery and development of small-molecule inhibitors of hypoxia-inducible factor-1 (HIF-1) is an attractive, yet challenging, strategy for the development of new cancer therapeutic agents. Here, we report on a novel tricyclic carboxamide inhibitor of HIF-1alpha, NSC 644221.
|
|
pubmed:affiliation |
Screening Technologies Branch, Developmental Therapeutics Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, Maryland 21702, USA.
|
